Clinical outcomes of resected EGFR positive stage I-III NSCLC patients in the Midlands, UK

被引：0
|
作者：
Powell, R. L. [1 ]
Murukesh, N. [2 ]
Seeva, P. [2 ]
Solanki, A. [3 ]
Singh, A. [3 ]
Jain, A. [4 ]
Elmasry, A. R. [5 ]
Jegannathen, A. [5 ]
Irwin, A. [6 ]
Ghafoor, Q. [6 ]
O'Sullivan, B. [6 ]
Taniere, P. [7 ]
Baijal, S. [8 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Clin Haematol & Oncol Dept, Heartlands Hosp, Birmingham, W Midlands, England
[2] Worcestershire Royal Hosp, Dept Oncol, Worcester, England
[3] Royal Wolverhampton NHS Trust, New Cross Hosp, Deanesly Ctr, Wolverhampton, England
[4] New Cross Hosp, Royal Wolverhampton Hosp NHS Trust, Wolverhampton, England
[5] Univ Hosp North Midlands, Stoke On Trent, Staffs, England
[6] New Queen Elizabeth Hosp Birmingham, Oncol, Birmingham, W Midlands, England
[7] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England
[8] Heart England NHS Fdn Trust, Heartlands Hosp, Birmingham, W Midlands, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67P
引用
收藏
页码：S731 / S732
页数：2
相关论文
共 50 条
  • [31] Ribonucleotide reductase subunit 2 (RRM2) predicts shorter survival in resected stage I-III non-small cell lung cancer (NSCLC) patients
    Grossi, F.
    Rijavec, E.
    Dal Bello, M. G.
    Savarino, G.
    Sini, C.
    Barletta, G.
    Genova, C.
    Truini, M.
    Pfeffer, U.
    Merlo, D. F.
    LUNG CANCER, 2012, 77 : S23 - S23
  • [32] RIBONUCLEOTIDE REDUCTASE SUBUNIT 2 (RRM2) PREDICTS SHORTER SURVIVAL IN RESECTED STAGE I-III NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Grossi, F.
    Barletta, G.
    Sini, C.
    Rijavec, E.
    Genova, C.
    Dal Bello, M. G.
    Savarino, G.
    Truini, M.
    Merlo, F.
    Pronzato, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 79 - 79
  • [33] RIBONUCLEOTIDE REDUCTASE SUBUNIT 2 (RRM2) PREDICTS SHORTER SURVIVAL IN RESECTED STAGE I-III NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Dal Bello, M. G.
    Savarino, G.
    Rijavec, E.
    Sini, C.
    Barletta, G.
    Genova, C.
    Truini, M.
    Merlo, D.
    Pfeffer, U.
    Grossi, F.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S30 - S30
  • [34] Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer
    Chaft, Jamie E.
    Dagogo-Jack, Ibiayi
    Santini, Fernando C.
    Eng, Juliana
    Yeap, Beow Y.
    Izar, Benjamin
    Chin, Emily
    Jones, David R.
    Kris, Mark G.
    Shaw, Alice T.
    Gainor, Justin F.
    LUNG CANCER, 2018, 122 : 67 - 71
  • [35] ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study
    Speel, E-J. M.
    Radonic, T.
    Dafni, U.
    Thunnissen, E.
    Ruschoff, J. H.
    Kowalski, J.
    Kerr, K. M.
    Bubendorf, L.
    Valero, I. Sansano
    Joseph, L.
    Navarro, A.
    Monkhorst, K.
    Madsen, L. B.
    Losa, J. Hernandez
    Biernat, W.
    Dellaporta, T.
    Kammler, R.
    Peters, S.
    Stahel, R. A.
    Finn, S. P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S144 - S145
  • [36] A multi-institutional study of outcomes in stage I-III uterine carcinosarcorna
    Dickson, Elizabeth L.
    Vogel, Rachel Isaksson
    Gehrig, Paola A.
    Pierce, Stuart
    Havrilesky, Laura
    Secord, Angeles Alvarez
    Dottino, Joseph
    Fader, Amanda N.
    Ricci, Stephanie
    Geller, Melissa A.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (02) : 275 - 282
  • [37] Clinico-Pathological Data and Prognostic Factors in Completely Resected AJCC Stage I-III Liposarcomas
    Paul H. A. Nijhuis
    Paul R. A. Sars
    Boudewijn E. C. Plaat
    Willemina M. Molenaar
    Wim J. Sluiter
    Harald J. Hoekstra
    Annals of Surgical Oncology, 2000, 7 : 535 - 543
  • [38] Surgical treatment experience for patients with stage I-III esophageal cancer
    Kolesnik, O. P.
    Kolesnyk, I. P.
    Kechedzhyiev, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2018, (03) : 448 - 453
  • [39] Clinico-pathological data and prognostic factors in completely resected AJCC stage I-III liposarcomas
    Nijhuis, PHA
    Sars, PRA
    Plaat, BEC
    Molenaar, WM
    Sluiter, WJ
    Hoekstra, HJ
    ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (07) : 535 - 543
  • [40] The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I-III resected NSCLC without known EGFR mutations.
    Gray, Jhanelle Elaine
    Salomonsen, Rachel
    Georgoulia, Nefeli
    Perez, Ignacio Diaz
    Wang, Alice
    Cai, Ling
    Wetherill, Graham
    Xiao, Yang
    Fielden, Claire
    Altorki, Nasser K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345